Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity

Predicting response to cancer immunotherapy is still a challenge. Here, the authors show that their method of predicting MHC-binding peptides, combined with profiling anti-immunogenic mutations, can better predict the clinical benefit of immunotherapy.

Guardado en:

Detalles Bibliográficos
Autores principales:	Kwoneel Kim, Hong Sook Kim, Jeong Yeon Kim, Hyunchul Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Se-Hoon Lee, Jung Kyoon Choi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/81e385970f0841be95673eae17dd1b1b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:81e385970f0841be95673eae17dd1b1b
record_format	dspace
spelling	oai:doaj.org-article:81e385970f0841be95673eae17dd1b1b2021-12-02T16:49:16ZPredicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity10.1038/s41467-020-14562-z2041-1723https://doaj.org/article/81e385970f0841be95673eae17dd1b1b2020-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-14562-zhttps://doaj.org/toc/2041-1723Predicting response to cancer immunotherapy is still a challenge. Here, the authors show that their method of predicting MHC-binding peptides, combined with profiling anti-immunogenic mutations, can better predict the clinical benefit of immunotherapy.Kwoneel KimHong Sook KimJeong Yeon KimHyunchul JungJong-Mu SunJin Seok AhnMyung-Ju AhnKeunchil ParkSe-Hoon LeeJung Kyoon ChoiNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-11 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Kwoneel Kim Hong Sook Kim Jeong Yeon Kim Hyunchul Jung Jong-Mu Sun Jin Seok Ahn Myung-Ju Ahn Keunchil Park Se-Hoon Lee Jung Kyoon Choi Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
description	Predicting response to cancer immunotherapy is still a challenge. Here, the authors show that their method of predicting MHC-binding peptides, combined with profiling anti-immunogenic mutations, can better predict the clinical benefit of immunotherapy.
format	article
author	Kwoneel Kim Hong Sook Kim Jeong Yeon Kim Hyunchul Jung Jong-Mu Sun Jin Seok Ahn Myung-Ju Ahn Keunchil Park Se-Hoon Lee Jung Kyoon Choi
author_facet	Kwoneel Kim Hong Sook Kim Jeong Yeon Kim Hyunchul Jung Jong-Mu Sun Jin Seok Ahn Myung-Ju Ahn Keunchil Park Se-Hoon Lee Jung Kyoon Choi
author_sort	Kwoneel Kim
title	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
title_short	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
title_full	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
title_fullStr	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
title_full_unstemmed	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
title_sort	predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/81e385970f0841be95673eae17dd1b1b
work_keys_str_mv	AT kwoneelkim predictingclinicalbenefitofimmunotherapybyantigenicorfunctionalmutationsaffectingtumourimmunogenicity AT hongsookkim predictingclinicalbenefitofimmunotherapybyantigenicorfunctionalmutationsaffectingtumourimmunogenicity AT jeongyeonkim predictingclinicalbenefitofimmunotherapybyantigenicorfunctionalmutationsaffectingtumourimmunogenicity AT hyunchuljung predictingclinicalbenefitofimmunotherapybyantigenicorfunctionalmutationsaffectingtumourimmunogenicity AT jongmusun predictingclinicalbenefitofimmunotherapybyantigenicorfunctionalmutationsaffectingtumourimmunogenicity AT jinseokahn predictingclinicalbenefitofimmunotherapybyantigenicorfunctionalmutationsaffectingtumourimmunogenicity AT myungjuahn predictingclinicalbenefitofimmunotherapybyantigenicorfunctionalmutationsaffectingtumourimmunogenicity AT keunchilpark predictingclinicalbenefitofimmunotherapybyantigenicorfunctionalmutationsaffectingtumourimmunogenicity AT sehoonlee predictingclinicalbenefitofimmunotherapybyantigenicorfunctionalmutationsaffectingtumourimmunogenicity AT jungkyoonchoi predictingclinicalbenefitofimmunotherapybyantigenicorfunctionalmutationsaffectingtumourimmunogenicity
_version_	1718383405962362880

Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity

Ejemplares similares